PASADENA, Calif.–(BUSINESS WIRE)—- $arwr–Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational plozasiran (formerly ARO-APOC3) in patients with severe hypertriglyceridemia (SHTG). Results from the SHASTA-2 study showed dramatic, consistent, and sustained reductions in Apolipoprotein C-III (APOC3) and…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
